HIV Vaccine Immunology

the trademark of a viral vaccine is to elicit robust, effective and extensive immune responses against the virus. One way of demonstrating that antibodies can elicit protection is by passive administration followed by virus challenge in in vivo models. A vaccine capable of eliciting satisfactory levels of antibody against HIV-1 could prevent the establishment of infection. In the case of HIV-1 the development of an effective vaccine has been an elusive one mainly due to the antigenic and genetic diversity of the virus. The development of an HIV vaccine is a crucial component required to bring the HIV/AIDS epidemic to an end. Vaccines can be either therapeutic or prophylactic. Therapeutic vaccines are designed to control/clear HIV from already infected individuals whereas prophylactic or preventive vaccines are designed to reduce the risk of infection in people who are not infected with HIV and also to reduce the viral load set point in people infected with HIV. Most of the research has been focused on the development of a preventive vaccine” Nageswara Rao A et al., The Pursuit of a HIV Vaccine Trials, Challenges and Strategies. Journal of Clinical and Cellular Immunology has considered this pioneering field of HIV research as a thrust area of immunology research and thus we made immense effort in compile articles related to this field of research.

• Share this page
• 
• 
• 
• 
• 
• 

Last date updated on September, 2024